Reading Time: < 1 minute Most of the buzz over Gilead Sciences (NASDAQ: GILD) in recent months has centered on its antiviral drug remdesivir. Read More
Reading Time: < 1 minute Over 50 percent of people in Taiwan hold negative impressions of people infected with HIV (human immunodeficiency virus) and AIDS, Read More
Reading Time: < 1 minute Most of the buzz over Gilead Sciences (NASDAQ: GILD) in recent months has centered on its antiviral drug remdesivir. Read More
Reading Time: < 1 minute ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders Read More